General Information of Drug Combination (ID: DC8MZXF)

Drug Combination Name
Ergonovine Oxytocin
Indication
Disease Entry Status REF
Cesarean Section Complications Phase 1 [1]
Component Drugs Ergonovine   DM0VEC1 Oxytocin   DMDL27I
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ergonovine
Disease Entry ICD 11 Status REF
Postpartum haemorrhage JA43 Approved [2]
Ergonovine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [7]
------------------------------------------------------------------------------------
Ergonovine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Indication(s) of Oxytocin
Disease Entry ICD 11 Status REF
Autism spectrum disorder 6A02 Approved [3]
Ductal breast carcinoma in situ N.A. Approved [4]
Postpartum haemorrhage JA43 Approved [4]
Lactation failure JB46.3 Phase 3 [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [6]
Oxytocin Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vasopressin V1b receptor (V1BR) TTL9MHW V1BR_HUMAN Agonist [9]
Vasopressin V2 receptor (V2R) TTK8R02 V2R_HUMAN Agonist [10]
Vasopressin V1a receptor (V1AR) TT4TFGN V1AR_HUMAN Agonist [11]
Oxytocin receptor (OTR) TTSCIUP OXYR_HUMAN Modulator [12]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Postpartum Hemorrhage DCXKHL5 N. A. Phase 1 [13]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03578263) Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 148).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2174).
4 Oxytocin FDA Label
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039450)
6 Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19)
7 Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9.
8 Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
9 The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
11 Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
13 ClinicalTrials.gov (NCT06285409) Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium